P2X Purinoceptor 3 (P2RX3) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘P2X Purinoceptor 3 (P2RX3) – Pipeline Review, H2 2016’, provides in depth analysis on P2X Purinoceptor 3 (P2RX3) targeted pipeline therapeutics.

The report provides comprehensive information on the P2X Purinoceptor 3 (P2RX3) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 3 (P2RX3)

The report reviews P2X Purinoceptor 3 (P2RX3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics and enlists all their major and minor projects

The report assesses P2X Purinoceptor 3 (P2RX3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to P2X Purinoceptor 3 (P2RX3) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 3 (P2RX3)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 3 (P2RX3) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Afferent Pharmaceuticals, Inc.

Asana BioSciences, LLC

Bayer AG

Integral Molecular, Inc.

Neurim Pharmaceuticals Ltd

Pfizer Inc.

Shionogi & Co., Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

P2X Purinoceptor 3 (P2RX3) Overview 7

Therapeutics Development 8

P2X Purinoceptor 3 (P2RX3) - Products under Development by Stage of Development 8

P2X Purinoceptor 3 (P2RX3) - Products under Development by Therapy Area 9

P2X Purinoceptor 3 (P2RX3) - Products under Development by Indication 10

P2X Purinoceptor 3 (P2RX3) - Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

P2X Purinoceptor 3 (P2RX3) - Products under Development by Companies 14

P2X Purinoceptor 3 (P2RX3) - Products under Development by Universities/Institutes 16

P2X Purinoceptor 3 (P2RX3) - Therapeutics Assessment 18

Assessment by Monotherapy/Combination Products 18

Assessment by Mechanism of Action 19

Assessment by Route of Administration 20

Assessment by Molecule Type 21

P2X Purinoceptor 3 (P2RX3) - Companies Involved in Therapeutics Development 23

Afferent Pharmaceuticals, Inc. 23

Asana BioSciences, LLC 24

Bayer AG 25

Integral Molecular, Inc. 26

Neurim Pharmaceuticals Ltd 27

Pfizer Inc. 28

Shionogi & Co., Ltd. 29

P2X Purinoceptor 3 (P2RX3) - Drug Profiles 30

AF-130 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

AF-219 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

ASN-009 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Drug to Antagonize P2X3 for Endometriosis - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Monoclonal Antibodies to Antagonize P2X3 Receptor for Pain - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

NEO-5937 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

OSX-300 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

OSX-300 Backups - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

piromelatine - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Small Molecule to Antagonize P2X3 Receptor for Neuropathic Pain - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

P2X Purinoceptor 3 (P2RX3) - Dormant Projects 45

P2X Purinoceptor 3 (P2RX3) - Discontinued Products 47

P2X Purinoceptor 3 (P2RX3) - Featured News & Press Releases 48

Sep 28, 2016: Neurim Pharmaceuticals Announces First Patients Enrollments in ReCOGNITION - Phase II Clinical Trial of Piromelatine for Mild Alzheimers Disease 48

Sep 05, 2016: Hypertension: releasing the pressure at its source 48

May 18, 2016: Afferent Pharmaceuticals Reports Cardiovascular Research Showing P2X3 Antagonism Successfully Reduces Hypertension By Restoring Autonomic Nervous Balance at the 2016 American Thoracic Society Conference 50

May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference 51

Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Chronic Cough Clinical Data at the Upcoming American Thoracic Society 2016 International Conference 53

Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Hypertension Research at the Upcoming American Thoracic Society 2016 International Conference 54

Dec 08, 2015: Afferent Pharmaceuticals Advances Novel Molecule, AF-130, to Phase 1 Clinical Trial 54

Nov 11, 2015: Afferent Pharmaceuticals Announces Phase 2 Clinical Trial with AF-219 in Cough in Idiopathic Pulmonary Fibrosis (IPF) Patients 55

Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial 55

Feb 26, 2015: Afferent Clinical Data for Lead Candidate, AF-219, Demonstrate Improvements in Pain and Urinary Urgency in Interstitial Cystitis / Bladder Pain Syndrome 56

Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet 57

Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company’s Lead P2X3 Antagonist, AF-219 58

Feb 18, 2013: Neurim Pharma Announces Positive Phase II Clinical Trial Results Of Piromelatine For Treatment Of Insomnia 59

Jul 24, 2011: Neurim Announces Positive Results From Phase I And Phase Ib Clinical Trials With Neu-P11 60

Aug 25, 2010: Afferent Reports Data Supporting Potential Utility Of P2X3 Antagonists In Lowering Bladder Reflexes 61

Appendix 62

Methodology 62

Coverage 62

Secondary Research 62

Primary Research 62

Expert Panel Validation 62

Contact Us 62

Disclaimer 63

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Stage and Mechanism of Action, H2 2016 19

Number of Products by Stage and Route of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 22

Pipeline by Afferent Pharmaceuticals, Inc., H2 2016 23

Pipeline by Asana BioSciences, LLC, H2 2016 24

Pipeline by Bayer AG, H2 2016 25

Pipeline by Integral Molecular, Inc., H2 2016 26

Pipeline by Neurim Pharmaceuticals Ltd, H2 2016 27

Pipeline by Pfizer Inc., H2 2016 28

Pipeline by Shionogi & Co., Ltd., H2 2016 29

Dormant Projects, H2 2016 45

Dormant Projects (Contd..1), H2 2016 46

Discontinued Products, H2 2016 47

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Stage and Mechanism of Actions, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 20

Number of Products by Molecule Types, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 21

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports